Veracyte (VCYT) Q2 Revenue Jumps 14%

Veracyte (NASDAQ:VCYT), a leader in advanced cancer diagnostics, reported results for Q2 2025 on August 6, 2025. The headline news: the company outperformed expectations on both revenue and profitability, driven by strong expansion in its core prostate cancer genomic testing platform. Revenue (GAAP) was $130.2 million, beating the average analyst estimate of $121.04 million (GAAP). Non-GAAP earnings per share reached $0.44 for Q2 2025, compared to the $0.26 GAAP EPS expectation. Management raised full-year 2025 total revenue guidance to $496 million to $504 million, underscoring continued traction in Decipher and improvements across its testing business. Overall, the quarter showed notable top-line growth, with GAAP total revenue increasing 14% to $130.2 million, expanding profitability, and increases in test volume, while also navigating one-time costs related to the wind-down of its French manufacturing operations. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Veracyte specializes in advanced genomic testing for cancer diagnosis and treatment guidance. Its main business is providing diagnostic tests that help clinicians more accurately diagnose and manage diseases such as thyroid, prostate, lung, and breast cancer. The company’s revenue comes primarily from its testing business, where physicians order genomic classifiers that aid treatment decisions.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool